Antibody treatment for triple-negative breast cancer
2015
University College Dublin, Dublin, Ireland
Nowadays, it is urgent to find an effective therapy targeted to triple-negative breast cancer. Current knowledge points towards epidermal growth factor receptor as a driver gene of the disease. Therefore, investigating the activation mechanisms of this gene could identify new targets for potential therapies. One of them could be ADAM-17, as the activation of the epidermal growth factor receptor depends on its mediated release of certain ligands. Here, a monoclonal antibody targeting ADAM-17 is tested in different human breast cancer cell lines cultured in different setups. The results show that the antibody significantly decreases epidermal growth factor receptor downstream signalling, reduces the proliferation of cancer cells in 2D and 3D conditions and induces cancer cell death. Moreover, it also inhibited cancer cell invasion and migration. In this study, the researchers validate the anticancer activity of an ADAM-17-directed antibody in different models of human breast cancer, which can potentially open the door to new opportunities in triple-negative breast cancer therapies.
Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
F Caiazza
Added on: 10-15-2021
[1] https://www.nature.com/articles/bjc2015163[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38
